MM 218

Drug Profile

MM 218

Latest Information Update: 09 Feb 2000

Price : $50

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Class Antidiarrhoeals; Antiemetics
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Diarrhoea; Irritable bowel syndrome

Most Recent Events

  • 09 Feb 2000 No-Development-Reported for Irritable bowel syndrome in Japan (Unknown route)
  • 09 Feb 2000 No-Development-Reported for Diarrhoea in Japan (Unknown route)
  • 16 Nov 1999 Tokyo Tanabe has been acquired by Mitsubishi Chemical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top